If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 61.50
Bid: 61.00
Ask: 62.00
Change: 0.50 (0.82%)
Spread: 1.00 (1.639%)
Open: 61.50
High: 61.50
Low: 61.00
Prev. Close: 61.00
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

18 Jul 2022 13:33

RNS Number : 8498S
Tissue Regenix Group PLC
18 July 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B5SGVL29

Issuer Name

TISSUE REGENIX GROUP PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Harwood Capital Management (Gibraltar) Limited

City of registered office (if applicable)

Gibraltar

Country of registered office (if applicable)

Gibraltar

4. Details of the shareholder

Name

City of registered office

Country of registered office

Oryx International Growth Fund Limited

Guernsey

Guernsey

Harwood Capital LLP

London

United Kingdom

5. Date on which the threshold was crossed or reached

15-Jul-2022

6. Date on which Issuer notified

18-Jul-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

18.080000

0.000000

18.080000

1272023849

Position of previous notification (if applicable)

14.040000

0.000000

14.040000

988000000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

Ordinary

750000000

10.660000

Ordinary

522023849

7.420000

Sub Total 8.A

1272023849

18.080000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Christopher Harwood Bernard Mills

Harwood Capital LLP

7.420000

7.420000%

Christopher Harwood Bernard Mills

Oryx International Growth Fund Limited

10.660000

10.660000%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

18-Jul-2022

13. Place Of Completion

London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUWOURURUBAAR
Date   Source Headline
14th Feb 20137:00 amRNSSuccessful safety study of dCELL® Meniscus
11th Feb 20132:57 pmRNSDirectorate Change
9th Jan 20137:15 amRNSHolding(s) in Company
30th Nov 201211:21 amRNSTissue Regenix board changes
26th Nov 20127:00 amRNSSets up US subsidiary
19th Nov 20127:00 amRNSAdds new patent global licence portfolio
4th Oct 20127:00 amRNSInterim data from clinical trial of dCELL® Dermis
4th Oct 20127:00 amRNSHalf Yearly Report
1st Oct 201210:57 amRNSTissue Regenix - senior development appointment
28th Sep 20123:30 pmRNSNotice of Results
7th Sep 20127:00 amRNSdCELL(R) vascular patch is safe and effective
2nd Aug 20122:31 pmRNSTissue Regenix makes appointment to Cardiac team
31st Jul 20123:02 pmRNSDirector/PDMR Shareholding
19th Jun 20122:39 pmRNSHolding(s) in Company
14th Jun 20127:00 amRNSResearch Update
11th Jun 201212:35 pmRNSResult of AGM
25th May 20127:00 amRNSExpands scope of development activities with NHSBT
10th May 20127:00 amRNSFinal Results
19th Apr 20121:49 pmRNSPoster shown at SAWC
16th Apr 20123:18 pmRNSNotice of Results
7th Feb 20124:00 pmRNSIssue of Equity and Total Voting Rights
11th Jan 201211:36 amRNSHolding(s) in Company
6th Jan 20125:05 pmRNSHolding(s) in Company
3rd Jan 20125:45 pmRNSHolding(s) in Company
3rd Jan 20125:43 pmRNSHolding(s) in Company
3rd Jan 20128:49 amRNSHolding(s) in Company
28th Dec 201112:00 pmRNSResult of General Meeting
8th Dec 201112:53 pmRNSIssue of Equity
25th Nov 20112:23 pmRNSUniversity Partner wins Queen's Anniversary Prize
4th Nov 20112:16 pmRNSHolding(s) in Company
14th Oct 20112:33 pmRNSHolding(s) in Company
10th Oct 20117:00 amRNSHalf Yearly Report
26th Jul 201111:04 amRNSIssue of Equity
7th Jul 20113:52 pmRNSIssue of Share Options
5th Jul 20111:30 pmRNSIssue of Equity
22nd Jun 20118:35 amRNSReceives EUR280,000 Grant Funding
13th Jun 20117:00 amRNSDirectorate Appointment
3rd Jun 201110:02 amRNSAGM Statement
11th May 20117:00 amRNSPositive Results in Clinical Evaluation of dCELL
4th May 20117:00 amRNSFinal Results
21st Apr 20117:00 amRNSTissue Regenix enters commercialisation agreement
29th Mar 20117:00 amRNSDirectorate Change
10th Mar 20117:00 amRNSNotice of allowance of patent received
4th Jan 201111:27 amRNSHolding(s) in Company
30th Dec 20109:05 amRNSHolding(s) in Company
23rd Dec 201012:44 pmRNSChange of Adviser
21st Dec 201010:12 amRNSAdviser - Change of Name
16th Dec 20107:00 amRNSResearch Update
10th Dec 20109:20 amRNSChange of Adviser
26th Nov 20103:12 pmRNSChange of Registered Office

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.